Eurosurv. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB l

[tetano]

• Liliana Antunes[SUP]1[/SUP] , Clara Mazagatos[SUP]2,3[/SUP] , Iván Martínez-Baz[SUP]4,5[/SUP] , Verónica Gomez[SUP]6[/SUP] , Maria-Louise Borg[SUP]7[/SUP] , Goranka Petrović[SUP]8[/SUP] , Róisín Duffy[SUP]9[/SUP] , François E Dufrasne[SUP]10[/SUP] , Ralf Dürrwald[SUP]11[/SUP] , Mihaela Lazar[SUP]12[/SUP] , Ligita Jancoriene[SUP]13[/SUP] , Beatrix Oroszi[SUP]14[/SUP] , Petr Husa[SUP]15[/SUP] , Jennifer Howard[SUP]1[/SUP] , Aryse Melo[SUP]16[/SUP] , Francisco Pozo[SUP]17[/SUP] , Gloria Pérez-Gimeno[SUP]2,3[/SUP] , Jesús Castilla[SUP]4,5[/SUP] , Ausenda Machado[SUP]6[/SUP] , Aušra Džiugytė[SUP]7[/SUP] , Svjetlana Karabuva[SUP]18[/SUP] , Margaret Fitzgerald[SUP]9[/SUP] , Sébastien Fierens[SUP]19[/SUP] , Kristin Tolksdorf[SUP]20[/SUP] , Silvia-Odette Popovici[SUP]21[/SUP] , Auksė Mickienė[SUP]22[/SUP] , Gergő Túri[SUP]14[/SUP] , Lenka Součková[SUP]15[/SUP] , Nathalie Nicolay[SUP]23[/SUP] , Angela MC Rose[SUP]1[/SUP] , on behalf of the European Hospital Vaccine Effectiveness Group[SUP]24[/SUP]

​We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708

 

[sharon sanders]

bump this